Influence of hepatitis viruses on clinico-pathological profiles and long-term outcome in patients undergoing surgery for hepatocellular carcinoma

Hepatobiliary and Pancreatic Diseases International

Volumn 13, Issue 2, 2014, Pages 162-172

  Tanase, Anna Maria ^a   Dumitrascu, Traian ^a   Dima, Simona ^a   Grigorie, Razvan ^a   Marchio, Agnes ^b   Pineau, Pascal ^b   Popescu, Irinel ^a  

^a FUNDENI CLINICAL INSTITUTE   (Romania)

^b INSTITUT PASTEUR   (France)

Author keywords

Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Prognosis; Recurrence

Indexed keywords

ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RADIOFREQUENCY ABLATION; TREATMENT OUTCOME; AGE; AGED; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; COMPARATIVE STUDY; COMPLICATION; EPIDEMIOLOGY; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PREVALENCE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; ROMANIA; TIME; VIROLOGY;

AGE FACTORS; AGED; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HEPATITIS B; HEPATITIS C; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM STAGING; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; ROMANIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84902574386     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-3872(14)60026-6     Document Type: Article

References (77)

1. Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am 2010;24: 899-919.
2. Capocaccia R, Sant M, Berrino F, Simonetti A, Santi V, Trevisani F, et al. Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol 2007;102:1661-1670.
3. Bahri O, Ezzikouri S, Alaya-Bouaff NB, Iguer F, Feydi AE, Mestiri H, et al. First multicenter study for risk factors for hepatocellular carcinoma development in North Africa. World J Hepatol 2011;3:24-30.
4. Acalovschi M, Pascu M, Iobagiu S, Ban A, Olinici DC, Petrescu M. Time trends in the incidence of hepatocellular carcinoma in liver cirrhosis. A retrospective necropsy study in a large Romanian town (1973-1992). Rom J Intern Med 1996;34:85-90.
5. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011;15:223-243.
6. Qian Y, Fan JG. Obesity, fatty liver and liver cancer. Hepatobiliary Pancreat Dis Int 2005;4:173-177.
7. Wang WM, Xu Y, Yang XR, Wang YH, Sun HX, Fan J. Prognostic role of diabetes mellitus in hepatocellular carcinoma patients after curative treatments: a meta-analysis. Hepatobiliary Pancreat Dis Int 2011;10:346-355.
8. Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol 2005;3:27.
9. Constantin CV, Streba CT, Rogoveanu I, Nita-Stefanescu L, Ionescu AG. Cirrhosis and chronic viral hepatitis as risk factors for hepatocellular carcinoma: Romanian single-clinic experience. Maedica (Buchar) 2010;5:265-270.
10. Perumalswami PV, Bini EJ. Epidemiology, natural history, and treatment of hepatitis B virus and hepatitis C virus coinfection. Minerva Gastroenterol Dietol 2006;52:145-155.
11. Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998;28:27-33.
12. Iizuka N, Oka M, Yamada-Okabe H, Hamada K, Nakayama H, Mori N, et al. Molecular signature in three types of hepatocellular carcinoma with different viral origin by oligonucleotide microarray. Int J Oncol 2004;24:565-574.
13. Marchio A, Pineau P, Meddeb M, Terris B, Tiollais P, Bernheim A, et al. Distinct chromosomal abnormality pattern in primary liver cancer of non-B, non-C patients. Oncogene 2000;19:3733-3738.
14. Blonski W, Reddy KR. Hepatitis C virus infection and hepatocellular carcinoma. Clin Liver Dis 2008;12:661-674.
15. Pawlik TM, Esnaola NF, Vauthey JN. Surgical treatment of hepatocellular carcinoma: similar long-term results despite geographic variations. Liver Transpl 2004;10:S74-80.
16. Tang ZY. Hepatocellular carcinoma surgery--review of the past and prospects for the 21st century. J Surg Oncol 2005;91: 95-96.
17. Dima SO, Iacob S, Botea F, Matei E, Dorobantu B, Vasile S, et al. Multimodal treatment of hepatocellular carcinoma: an eastern European experience. Hepatogastroenterology 2009;56:1696-1703.
18. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127: S35-50.
19. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 2008;7:237-257.
20. Masaki T, Morishita A, Kurokohchi K, Kuriyama S. Multidisciplinary treatment of patients with hepatocellular carcinoma. Expert Rev Anticancer Ther 2006;6:1377-1384.
21. Zhou XD, Tang ZY, Ma ZC, Fan J, Wu ZQ, Qin LX, et al. Twenty-year survivors after resection for hepatocellular carcinoma-analysis of 53 cases. J Cancer Res Clin Oncol 2009;135:1067-1072.
22. Zhou Y, Si X, Wu L, Su X, Li B, Zhang Z. Influence of viral hepatitis status on prognosis in patients undergoing hepatic resection for hepatocellular carcinoma: a meta-analysis of observational studies. World J Surg Oncol 2011;9:108.
23. Ivan A, Danet D, Iancu L, Tiron S, Ungureanu A, Zavate O. Clinico-epidemiologic and laboratory studies of patients with primary hepatocellular carcinoma. Rev Med Chir Soc Med Nat Iasi 1989;93:735-740.
24. Kanazir M, Boricic I, Delic D, Tepavcevic DK, Knezevic A, Jovanovic T, et al. Risk factors for hepatocellular carcinoma: a case-control study in Belgrade (Serbia). Tumori 2010;96: 911-917.
25. Marchio A, Tanase AM, Dumitrascu T, Mihaila M, Dima S, Dejean A, et al. High chromosome instability and occasional R249S TP53 mutation characterize hepatocellular carcinoma in Romania. Cancer Genet Cytogenet 2010;203:73.
26. Galun DA, Bulajic P, Zuvela M, Basaric D, Ille T, Milicevic MN Is there any beneft from expanding the criteria for the resection of hepatocellular carcinoma in cirrhotic liver? Experience from a developing country. World J Surg 2012;36: 1657-1665.
27. Cescon M, Cucchetti A, Grazi GL, Ferrero A, Viganò L, Ercolani G, et al. Role of hepatitis B virus infection in the prognosis after hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a Western dual-center experience. Arch Surg 2009;144:906-913.
28. Gheorghe L, Csiki IE, Iacob S, Gheorghe C, Smira G, Regep L. The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: a nationwide survey 2006-2008. J Gastrointestin Liver Dis 2010;19:373-379.
29. Gheorghe L, Csiki IE, Iacob S, Gheorghe C. The prevalence and risk factors of hepatitis B virus infection in an adult population in Romania: a nationwide survey. Eur J Gastroenterol Hepatol 2013;25:56-64.
30. Grigorescu M; Romanian Society of Gastroenterology and Hepatology. HCV genotype 1 is almost exclusively present in Romanian patients with chronic hepatitis C. J Gastrointestin Liver Dis 2009;18:45-50.
31. Nardone A, Anastassopoulou CG, Theeten H, Kriz B, Davidkin I, Thierfelder W, et al. A comparison of hepatitis B seroepidemiology in ten European countries. Epidemiol Infect 2009;137:961-969.
32. Paquet C, Babes VT, Drucker J, Sénémaud B, Dobrescu A. Viral hepatitis in Bucharest. Bull World Health Organ 1993; 71:781-786.
33. Voiculescu M, Iliescu L, Ionescu C, Micu L, Ismail G, Zilisteanu D, et al. A cross-sectional epidemiological study of HBV, HCV, HDV and HEV prevalence in the SubCarpathian and South-Eastern regions of Romania. J Gastrointestin Liver Dis 2010;19:43-48.
34. Iarovoi P, Rimis C, Spinu C, Isac M. Epidemiology of hepatitis B virus infection in the Republic of Moldova. J Infect Dev Ctries 2008;2:190-192.
35. Atanasova MV, Haydouchka IA, Zlatev SP, Stoilova YD, Iliev YT, Mateva NG. Prevalence of antibodies against hepatitis C virus and hepatitis B coinfection in healthy population in Bulgaria. A seroepidemiological study. Minerva Gastroenterol Dietol 2004;50:89-96.
36. Ahmad SA, Bilimoria MM, Wang X, Izzo F, Delrio P, Marra P, et al. Hepatitis B or C virus serology as a prognostic factor in patients with hepatocellular carcinoma. J Gastrointest Surg 2001;5:468-476.
37. Gao JD, Shao YF, Xu Y, Ming LH, Wu ZY, Liu GT, et al. Tight association of hepatocellular carcinoma with HBV infection in North China. Hepatobiliary Pancreat Dis Int 2005;4:46-49.
38. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009;361:1437-1447.
39. Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE. Hepatocellular carcinoma confrmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology 2012;55:476-482.
40. Bréchot C, Jaffredo F, Lagorce D, Gerken G, Meyer Zum Büschenfelde K, et al. Impact of HBV, HCV and GBV-C/ HGV on hepatocellular carcinomas in Europe: results of a European concerted action. J Hepatol 1998;29:173-183.
41. Deuffc S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet 1998;351:214-215.
42. El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001;5:87-107.
43. Raza SA, Clifford GM, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer 2007;96:1127-1134.
44. Pitigoi D, Rafla A, Pistol A, Arama V, Molagic V, Streinu-Cercel A. Trends in hepatitis B incidence in Romania, 1989-2005. Euro Surveill 2008;13:pii=8012.
45. Bara AC, van den Heuvel WJ, Maarse JA. Reforms of health care system in Romania. Croat Med J 2002;43:446-452.
46. Katsaga A, Kulzhanov M, Karanikolos M, Rechel B. Kazakhkstan health system review. Health Syst Transit 2012; 14:1-154.
47. Kondo K, Chijiiwa K, Kai M, Otani K, Nagaike K, Ohuchida J, et al. Surgical strategy for hepatocellular carcinoma patients with portal vein tumor thrombus based on prognostic factors. J Gastrointest Surg 2009;13:1078-1083.
48. Li Q, Li H, Qin Y, Wang PP, Hao X. Comparison of surgical outcomes for small hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a Chinese experience. J Gastroenterol Hepatol 2007;22:1936-1941.
49. Fletcher O, Houlston RS. Architecture of inherited susceptibility to common cancer. Nat Rev Cancer 2010;10: 353-361.
50. Frank SA. Genetic predisposition to cancer - insights from population genetics. Nat Rev Genet 2004;5:764-772.
51. Draper GJ. The analysis of registry data in relation to various different types of hypothesis regarding the geographical distribution of disease. Cent Eur J Public Health 1997;5:90-92.
52. Kao WY, Su CW, Chau GY, Lui WY, Wu CW, Wu JC. A comparison of prognosis between patients with hepatitis B and C virus-related hepatocellular carcinoma undergoing resection surgery. World J Surg 2011;35:858-867.
53. Lee WC, Jeng LB, Chen MF. Hepatectomy for hepatitis B-, hepatitis C-, and dual hepatitis B- and C-related hepatocellular carcinoma in Taiwan. J Hepatobiliary Pancreat Surg 2000;7:265-269.
54. Sasaki Y, Yamada T, Tanaka H, Ohigashi H, Eguchi H, Yano M, et al. Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma. Ann Surg 2006;244:771-780.
55. Manzat Saplacan RM, Mircea PA, Valean SD, Miu N, Burac L, Valean C, et al. The long-term evolution of chronic hepatitis B acquired in childhood. J Gastrointestin Liver Dis 2009;18:433-438.
56. Pineau P, Tiollais P. Hepatitis B vaccination: a major player in the control of primary liver cancer. Pathol Biol (Paris) 2010;58:444-453.
57. Liu Z, Hou J. Hepatitis B virus (HBV) and hepatitis C virus (HCV) dual infection. Int J Med Sci 2006;3:57-62.
58. Hartleb M, Gutkowski K, Zejda JE, Chudek J, Wiecek A. Serological prevalence of hepatitis B virus and hepatitis C virus infection in the elderly population: Polish nationwide survey--PolSenior. Eur J Gastroenterol Hepatol 2012;24:1288-1295.
59. Nalpas B, Zylberberg H, Dubois F, Presles MA, Gillant JC, Lienard M, et al. Prevalence of infection by hepatitis viruses in a rural area. Analysis according to risk factors and alcohol consumption. Gastroenterol Clin Biol 2000;24:536-540.
60. Shimbo S, Zhang ZW, Qu JB, Wang JJ, Zhang CL, Song LH, et al. Urban-rural comparison of HBV and HCV infection prevalence among adult women in Shandong Province, China. Southeast Asian J Trop Med Public Health 1997;28: 500-506.
61. Cinteza M, Pana B, Cochino E, Florescu M, Margulescu A, Florian A, et al. Prevalence and control of cardiovascular risk factors in Romania cardio-zone national study. Maedica (Buchar) 2007;4:277-288.
62. Prejbeanu I, Rada C, Indrei LL, Cara ML, Mihai M, Dragomir M, et al. Smoking, alcohol consumption and pregnancy in a population of south-western Romania. Rev Med Chir Soc Med Nat Iasi 2010;114:1148-1154.
63. Gulis G, Kollarová J, Dietzová Z, Labancová J, Behanová M, Ondrusová M. Natural and man-made health hazards in rural Slovakia. Cent Eur J Public Health 2009;17:207-214.
64. Smailyte G, Kurtinaitis J. Cancer mortality differences among urban and rural residents in Lithuania. BMC Public Health 2008;8:56.
65. Brechot C, Kremsdorf D, Soussan P, Pineau P, Dejean A, Paterlini-Brechot P, et al. Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC): molecular mechanisms and novel paradigms. Pathol Biol (Paris) 2010;58:278-287.
66. Bralet MP, Régimbeau JM, Pineau P, Dubois S, Loas G, Degos F, et al. Hepatocellular carcinoma occurring in nonfbrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology 2000;32:200-204.
67. Barazani Y, Hiatt JR, Tong MJ, Busuttil RW. Chronic viral hepatitis and hepatocellular carcinoma. World J Surg 2007; 31:1243-1248.
68. Bukhtiari N, Hussain T, Iqbal M, Malik AM, Qureshi AH, Hussain A. Hepatitis B and C single and co-infection in chronic liver disease and their effect on the disease pattern. J Pak Med Assoc 2003;53:136-140.
69. Noguchi K, Nakashima O, Nakashima Y, Shiota K, Nawata H, Kojiro M. Clinicopathologic study on hepatocellular carcinoma negative for hepatitis B surface antigen and antibody to hepatitis C virus. Int J MolMed 2000;6:661-665.
70. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75:347-354.
71. Shiraishi M, Hiroyasu S, Nagahama M, Tomita S, Miyahira T, Kusano T, et al. Characteristics of hepatocellular carcinoma in patients with negative virus markers: clinicopathologic study of resected tumors. World J Surg 1999;23:301-305.
72. Nanashima A, Abo T, Sumida Y, Takeshita H, Hidaka S, Furukawa K, et al. Clinicopathological characteristics of patients with hepatocellular carcinoma after hepatectomy: relationship with status of viral hepatitis. J Surg Oncol 2007; 96:487-492.
73. Chen JD, Liu CJ, Lee PH, Chen PJ, Lai MY, Kao JH, et al. Hepatitis B genotypes correlate with tumor recurrence after curative resection of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2004;2:64-71.
74. Miao RY, Zhao HT, Yang HY, Mao YL, Lu X, Zhao Y, et al. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. World J Gastroenterol 2010;16:2931-2942.
75. Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006;132: 458-465.
76. Zhang T, Sun HC, Zhou HY, Luo JT, Zhang BL, Wang P, et al. Interferon alpha inhibits hepatocellular carcinoma growth through inducing apoptosis and interfering with adhesion of tumor endothelial cells. Cancer Lett 2010;290:204-210.
77. Zhuang PY, Zhang JB, Zhang W, Zhu XD, Liang Y, Xu HX, et al. Long-term interferon-a treatment suppresses tumor growth but promotes metastasis capacity in hepatocellular carcinoma. J Cancer Res Clin Oncol 2010;136:1891-1900.